T cell production method

By using fibroblasts derived from human iPS cells as stromal cells, T cell differentiation is induced in the ATO method, safety and stability problems in the existing technology are solved, and high safety and efficient T cell production is achieved, improving the production of high safety and high efficiency. Anti-cancer activity and cell kinetic properties.

CN118946661APending Publication Date: 2024-11-12KYOTO UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030490.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-04
Filing Date
2023-02-03
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing T cell production methods have safety and stability problems, especially when using mouse stromal cells, there is a risk of heterologous and batch-to-batch variability, and human fibroblasts as feeder cells may pose a risk of cancer cells.

Method used

Fibroblasts derived from human iPS cells are used as stromal cells and used as feeder cells in artificial thymus organoids (ATO) method. T cell differentiation is induced by expressing Notch ligands such as DLL4 to ensure the safety of the production process. and consistency.

Benefits of technology

T cell production with high safety in production is achieved, reducing inter-batch variability, and improving the anti-cancer activity and cell dynamics of T cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005060156480000271
    Figure BDA0005060156480000271
  • Figure BDA0005060156480000281
    Figure BDA0005060156480000281
  • Figure HDA0005060156500000011
    Figure HDA0005060156500000011
Patent Text Reader

Abstract

Disclosed is a method for producing T cells, the method comprising: a step (1) of culturing a three-dimensional cell aggregate comprising cells that can be differentiated into T cells and stromal cells that express Notch ligands derived from pluripotent stem cells. A T cell obtained by the method and a drug comprising the T cell are also disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for producing T cells, T cells obtained by the method, a drug containing T cells, and the like. Background Art

[0002] In recent years, research and development of various cell therapies using T cells (e.g., CAR T cell therapy and regulatory T cell (Treg cell) therapy) have been actively promoted worldwide. When inducing iPS cells to differentiate into T cells, conventional 2D culture methods are known to mainly induce CD8 single positive (SP) T cells, and it is difficult to induce other T cells (e.g., CD4 SP T cells).

[0003] On the other hand, PTL 1 and NPL 1 disclose a method for preparing a T cell composition from stem cells or progenitor cells by culturing three-dimensional cell aggregates comprising a selected Notch ligand-expressing stromal cell population and a selected stem cell or progenitor cell population, which is referred to as an artificial thymic organoid (ATO) method.

[0004] In addition, PTL 2 discloses a gene encoding a gene that promotes differentiation into CD4 + Genetically engineered mammalian cells transgenic for Treg lineage commitment factors.

[0005] Citation List

[0006] Patent Literature

[0007] PTL 1: WO2017 / 075389

[0008] PTL 2: WO2021 / 092581

[0009] Non-patent literature

[0010] NPL 1: Nat.Methods,14,521-530(2017) Summary of the invention

[0011] Technical issues

[0012] An object of the present invention is to provide a method for producing T cells with high safety in production.

[0013] Solution to the problem

[0014] As described above, the ATO method is known as a method for inducing differentiation of iPS cells, etc., into various T cells (CD4 SP cells, CD8 SP cells, γδT cells, regulatory T cells, etc.). In the ATO method, mouse stromal cells are generally used as feeder cells; however, considering production barriers from the perspective of good manufacturing procedures (GMP), it is preferred to use a xeno-free method.

[0015] However, no xeno-free methods have been reported to date. For example, when primary human fibroblasts are used as feeder cells, disadvantages include limited proliferation capacity and / or large donor-dependent or batch-to-batch variations. In contrast, when human fibroblast cell lines are used as feeder cells, there are no disadvantages of using primary human fibroblasts; however, the disadvantage is that since they are cancer cells, there is the possibility of increased risk in clinical applications.

[0016] As a result of extensive studies to achieve the above-mentioned purpose, the present inventors found that a method for producing T cells with high safety in production can be provided by producing stromal cells (particularly fibroblasts) derived from human iPS cells and using them as feeder cells in the ATO method.

[0017] The present invention was completed after further investigation based on this finding. The present invention provides the following method for producing T cells, T cells, drugs, etc.

[0018] [1] A method for producing T cells, the method comprising:

[0019] Step (1) culturing three-dimensional cell aggregates, wherein the three-dimensional cell aggregates contain cells capable of differentiating into T cells and matrix cells derived from pluripotent stem cells and expressing Notch ligands.

[0020] [2] The method according to [1], wherein the cells capable of differentiating into T cells are CD34 + cells or mesodermal progenitor cells.

[0021] [3] The method according to [1], wherein the cell capable of differentiating into a T cell is a hematopoietic stem cell, a hematopoietic endothelial cell, a progenitor T cell, or a mesodermal progenitor cell.

[0022] [4] The method according to [1], wherein the cells capable of differentiating into T cells are hematopoietic endothelial cells.

[0023] [5] The method according to any one of [1] to [4], wherein the cells capable of differentiating into T cells are cells derived from pluripotent stem cells.

[0024] [6] The method according to any one of [1] to [5], wherein the cell capable of differentiating into a T cell is a cell derived from an iPS cell.

[0025] [6a] The method according to any one of [1] to [6], wherein the cell capable of differentiating into a T cell is a cell derived from a human iPS cell.

[0026] [7] The method according to any one of [1] to [6a], wherein the stromal cells are fibroblasts.

[0027] [8] The method according to any one of [1] to [7], wherein the pluripotent stem cells are iPS cells.

[0028] [8a] The method according to any one of [1] to [8], wherein the pluripotent stem cells are human iPS cells.

[0029] [9] The method according to any one of [1] to [8a], wherein the Notch ligand is at least one member selected from the group consisting of DLL4, DLL1, JAG1 and JAG2.

[0030]

[10] The method according to any one of [1] to [9], further comprising, before step (1):

[0031] Step (2) inducing pluripotent stem cells to differentiate into stromal cells.

[0032]

[11] The method according to any one of [6] to

[10] , further comprising, before step (1):

[0033] Step (3) induces iPS cells to differentiate into cells capable of differentiating into T cells.

[0034]

[12] The method according to any one of [1] to

[11] , further comprising, before step (1):

[0035] Step (4) introduces nucleic acid encoding exogenous T cell receptor and / or chimeric antigen receptor into cells capable of differentiating into T cells.

[0036]

[13] The method according to

[11] or

[12] , further comprising, before step (3):

[0037] Step (5) introduces nucleic acid encoding exogenous T cell receptor and / or chimeric antigen receptor into iPS cells.

[0038]

[14] The method according to any one of [1] to

[13] , which is a method for producing T cells, wherein the T cells contain a protein selected from the group consisting of CD4 + T cells, CD8 +At least one of the group consisting of T cells, γδ T cells and regulatory T cells.

[0039] [14a] The method according to any one of [1] to

[13] , which is a method for producing T cells, wherein the T cells contain a protein selected from the group consisting of CD4 + T cells, CD8 + At least one of the group consisting of T cells and γδ T cells.

[0040] [14b] A cell population derived from pluripotent stem cells, wherein the αβT cells contained in the cell population are CD4 + T cells and CD8 + The ratio of T cells is 0.6 or more.

[0041]

[15] T cells obtained by the method of any one of [1] to [14a].

[0042]

[16] A medicine comprising the T cells according to

[15] .

[0043]

[17] A method for producing T cells expressing exogenous T cell receptors and / or chimeric antigen receptors, comprising:

[0044] Step (6) introduces a nucleic acid encoding an exogenous T cell receptor and / or a chimeric antigen receptor into the T cells obtained by the method described in any one of [1] to [14a].

[0045]

[18] The drug according to

[16] , which is a preventive and / or therapeutic agent for T cell-related diseases.

[0046]

[19] The drug according to

[18] , wherein the T cell-related disease is a tumor, an infection or a blood disease.

[0047] [19a] The drug according to

[18] , wherein the T cell-related disease is an abnormally enhanced immune response.

[0048]

[20] A method for preventing and / or treating a T cell-related disease, comprising administering the T cells described in

[15] to a subject in need thereof.

[0049]

[21] The method according to

[20] , wherein the T cell-related disease is a tumor, an infection or a blood disease.

[0050] [21a] The method according to

[20] , wherein the T cell-related disease is an abnormally enhanced immune response.

[0051]

[22] The T cell according to

[15] , which is used for preventing and / or treating a T cell-related disease.

[0052]

[23] The T cell according to

[22] , wherein the T cell-related disease is a tumor, infection or blood disease.

[0053] [23a] The T cell according to

[22] , wherein the T cell-related disease is an abnormally enhanced immune response.

[0054]

[24]

[15] The use of the T cells described in the production of drugs for preventing and / or treating T cell-related diseases.

[0055]

[25] The use according to

[24] , wherein the T cell-related disease is a tumor, infection or blood disease.

[0056] [25a] The use according to

[24] , wherein the T cell-related disease is an abnormally enhanced immune response.

[0057] Advantageous Effects of the Invention

[0058] The present invention provides a method for producing T cells with high safety in production. In addition, in the production method of the present invention, stromal cells derived from pluripotent stem cells are used as feeder cells, so that the batch-to-batch variation of the feeder cells used is small, and T cells can be stably produced. According to an embodiment of the present invention, T cells with excellent anticancer activity can be produced. In addition, according to an embodiment of the present invention, T cells with excellent cell dynamics can be produced. BRIEF DESCRIPTION OF THE DRAWINGS

[0059] Figure 1 Shown are the expression of fibroblast markers CD90 and DLL4 in iPS cell-derived fibroblasts and the results of flow cytometric analysis of MS5 into which the human DLL4 gene was introduced.

[0060] Figure 2 The results of flow cytometric analysis of CD3 / TCRαβ, CD4 / CD8α, CD8α / CD8β, and CAR / IL15Rα after inducing iPS cells to differentiate into T cells are shown. From top to bottom, the results of FfI01s04+MS5 / DLL4, FfI01s04+iFibro / DLL4, QHJI01s04 / G9D2+MS5 / DLL4, and QHJI01s04 / G9D2+iFibro / DLL4 are shown.

[0061] Figure 3 Photographs illustrating the in vivo drug efficacy of iPS cell-derived CD19CAR T cells are shown. From top to bottom, the results 1, 2, 3, 4, and 5 weeks after administration are shown.

[0062] Figure 4: is a graph showing the in vivo cell dynamics of iPS cell-derived CD19CAR T cells. The cell numbers after 1, 2, 3, 4, and 5 weeks after cell administration are shown, and the values ​​in the graph are mean ± SD.

[0063] Figure 5 The results of examining the expression levels of proteins expressed in Tregs differentiated from iPS cells by using iPS cell-derived fibroblasts are shown. The dot plots in each figure show CD3 + CD4 + CD8 - In addition, the numbers in each figure indicate the number of Treg (CD3 + / CD4 + / CD8 - / CD25 + / FOXP3 + ) ratio. DETAILED DESCRIPTION

[0064] The embodiments of the present invention are described in detail below.

[0065] The term "comprise (comprise(s) / comprising)" means that although the elements after these terms are included, the inclusion is not limited to the elements. Therefore, these terms indicate that the elements thereafter are included, but do not indicate that any other elements are excluded. The term "consist(s) of / consisting of" means that any element after these terms is included, and the inclusion is limited to the elements. Therefore, the term "consist(s) of / consisting of" means that the listed elements are required or necessary, and there are basically no other elements. The term "essentially consisting of (consist(s) essentially of / consisting essentially of)" means that any element after these terms is included, and there are restrictions on other elements that do not affect the activity or effect specified by the above-mentioned elements in the present disclosure. Thus, the term "consist(s) essentially of / consisting essentially of" means that the listed elements are required or essential, while other elements are optional and may or may not be present, depending on whether they affect the activity or action of the listed elements.

[0066] In this specification, the term "culture" refers to the maintenance and / or proliferation of cells in an in vitro environment. The term "culture" refers to the maintenance and / or proliferation of cells outside a tissue or in vitro (eg, in a cell culture dish or flask).

[0067] In this specification, the term "positive (+)" means that the protein or gene is expressed in an amount detectable by methods known in the art. In the case where the protein is expressed intracellularly and does not appear on the cell surface (e.g., transcription factor or its subunit), the reporter protein is expressed together with the protein, and the reporter protein is detected, whereby the target protein can be detected. Gene detection can be performed using nucleic acid amplification and / or nucleic acid detection methods, such as RT-PCR, microarrays, biochips, and RNAseq.

[0068] In the present specification, the term "negative (-)" means that the expression level of a protein or gene is lower than the detection limit by all or any of the above-mentioned known methods. The detection limit of protein or gene expression may vary depending on the method.

[0069] In this specification, the term "marker" refers to a protein or its gene specifically expressed on the cell surface, in the cytoplasm or in the nucleus of a given cell type. Marker is preferably a "cell surface marker". "Cell surface marker" refers to a protein expressed on the cell surface, which can be labeled (stained) with a fluorescent substance and promotes the detection, concentration, separation, etc. of cells expressing cell surface markers. Cell surface markers refer to genes specifically expressed (positive markers) or not specifically expressed (negative markers) in a given cell type, and specifically refer to a substance that is produced (positive markers) or not produced (negative markers) by the transcription of the gene in the genome as mRNA or produced (positive markers) or not produced (negative markers) as protein by the translation of mRNA.

[0070] Such cell surface markers can be detected by immunological assays such as ELISA, immunostaining, and flow cytometry using antibodies specific for the cell surface markers.

[0071] In this specification, the term "expression" is defined as the transcription and / or translation of a specified nucleotide sequence driven by a promoter in a cell.

[0072] In this specification, "pluripotent stem cells" refer to embryonic stem cells (ES cells) and cells with similar pluripotency, that is, cells with the potential to differentiate into various tissues (endoderm, mesoderm and ectoderm) of a living body. Examples of cells with the same pluripotency as ES cells include induced pluripotent stem cells (also referred to as "iPS cells" in this specification).

[0073] In this specification, "hematopoietic stem cells (HSC)" are multipotent stem cells that can differentiate into blood cells. Hematopoietic stem cells are mainly present in the bone marrow of living humans, and differentiate into white blood cells (neutrophils, eosinophils, basophils, lymphocytes, monocytes and macrophages), red blood cells, platelets, mast cells, dendritic cells, etc. In this specification, hematopoietic stem cells (HSC) can be CD34 positive and CD7 negative (CD34 + / CD7 - ). In this specification, the phrase "CD34 + / CD7 - " / " used in " means "and".

[0074] In this specification, "hemogenic endothelial cells (HEC)" are cells that express CD34 but do not express CD43, CD184, and CD73 (CD34 + / CD43 - / CD184 - / CD73 - )(CD34 + / CD43 - / CD184 - / CD73 - Cells do not express CD7 and are therefore also referred to as "CD34 + / CD7 - / CD43 - / CD184 - / CD73 - cell").

[0075] In this specification, "pro-T cells (proT)" refer to hematopoietic cells generated in the process of differentiation from hematopoietic stem cells into CD3-positive T cells in human living bodies, and are CD34 and CD7 (CD34 + / CD7 + In addition, in the present specification, proT may be negative for CD43, CD1a and / or CD116.

[0076] In this specification, "mesoderm progenitor cells" refer to cells expressing at least one marker gene selected from the group consisting of T (synonymous with Brachyury), KDR, FOXF1, FLK1, BMP4, MOX1 and SDF1, for example. Mesodermal progenitor cells are not distinguished from mesodermal cells. Cells that weakly express the above marker genes may be referred to as "mesoderm progenitor cells".

[0077] In this specification, "CD4CD8 double positive T cells" refers to T cells that are positive for both surface antigens CD4 and CD8 (CD8 + / CD4+ Since T cells can be identified by the positive surface antigens CD3 and CD45, CD4CD8 double positive T cells can be identified as cells that are positive for CD4, CD8, CD3 and CD45 (CD8 + / CD4 + / CD3 + / CD45 + cell).

[0078] In this specification, "CD4CD8 double negative T cells" refers to T cells whose surface antigens CD4 and CD8 are both negative (CD8 - / CD4 - Since T cells can be identified by the positivity of the surface antigens CD3 and CD45, CD4CD8 double negative T cells can be identified as cells that are negative for CD4 and CD8 and positive for CD3 and CD45 (CD8 - / CD4 - / CD3 + / CD45 + cell).

[0079] In the present invention, hematopoietic stem cells, hematopoietic endothelial cells, progenitor T cells, mesodermal progenitor cells, CD4CD8 double-positive T cells and CD4CD8 double-negative T cells may be cells isolated from biological tissues (such as bone marrow, umbilical cord blood and blood), or may be cells derived from pluripotent stem cells (such as ES cells and iPS cells).

[0080] In this manual, "CD4 + T cells refer to T cells whose surface antigens are positive for CD4 and negative for CD8 (CD4 + / CD8 - ) cells. Since T cells can be identified by positive surface antigens CD3 and CD45, CD4 + T cells can be identified as cells that are negative for CD8 and positive for CD4, CD3, and CD45 (CD4 + / CD8 - / CD3 + / CD45 + cells). CD4 + Examples of T cells include helper T cells.

[0081] In this manual, "CD8 + T cells refer to T cells whose surface antigens are positive for CD8 and negative for CD4 (CD8 + / CD4 - Since T cells can be identified by positive surface antigens CD3 and CD45, CD8 +T cells can be identified as cells that are negative for CD4 and positive for CD8, CD3, and CD45 (CD4 - / CD8 + / CD3 + / CD45 + cells). CD8 + Examples of T cells include cytotoxic T cells.

[0082] In the present specification, "γδT cells" refer to cells that express CD3 and also express a T cell receptor (TCR) composed of a TCRγ chain (γTCR) and a TCRδ chain (δTCR).

[0083] In the present specification, “αβ T cells” refer to cells that express CD3 and also express a T cell receptor (TCR) composed of a TCR α chain (αTCR) and a TCR β chain (βTCR).

[0084] In this specification, "regulatory T cells" refer to T cells that have the ability to inhibit the activation of effector T cells when stimulated via T cell receptors and are responsible for suppressing immune responses (immune tolerance). Regulatory T cells are usually CD25 + / FOXP3 + cells, and the presence of CD4 + or CD8 + In the present invention, regulatory T cells can be CD4 + Cells (i.e. CD4 + / CD25 + / FOXP3 + ) or CD8 + Cells (i.e. CD8 + / CD25 + / FOXP3 + ), more preferably CD4 + cells, even more preferably CD4 + / CD8 - / CD25 + / FOXP3 + In addition, the transcription factor FOXP3 is known to be a CD4 + / CD25 + Master regulator of regulatory T cells.

[0085] In the present specification, "cell population" refers to two or more cells of the same or different types. The term "cell population" also refers to a large number of cells of the same or different types.

[0086] From the viewpoint of therapeutic application, the various cells used in the present invention are preferably GMP-compliant cells.

[0087] Examples of pluripotent stem cells include embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), embryonic carcinoma cells (EC cells), embryonic germ stem cells (EG cells) and Muse cells; and preferably iPS cells (more preferably human iPS cells). When the pluripotent stem cell is an ES cell or any cell derived from a human embryo, cells can be produced by destroying the embryo or not, and preferably the cells produced without destroying the embryo.

[0088] Regarding “ES cells”, various mouse ES cell strains established by Ingenious Targeting Laboratory, RIKEN, etc. can be used as mouse ES cells, and various human ES cell strains established by the University of Wisconsin, NIH, RIKEN, Kyoto University, National Center for Child Health and Development, Cellartis, etc. can be used as human ES cells. Available examples of human ES cell strains include CHB-1 to CHB-12 strains, RUES1 strains, RUES2 strains, HUES1 to HUES28 strains, etc. provided by ESI Bio; H1 strains, H9 strains, etc. provided by WiCell Research; and KhES-1 strains, KhES-2 strains, KhES-3 strains, KhES-4 strains, KhES-5 strains, SSES1 strains, SSES2 strains, SSES3 strains, etc. provided by RIKEN.

[0089] "Induced pluripotent stem cells" refer to cells obtained by reprogramming mammalian somatic cells or undifferentiated stem cells by introducing specified factors (nuclear reprogramming factors). Currently, there are many different types of induced pluripotent stem cells. Available examples include iPS cells established by Yamanaka et al. by introducing four factors Oct3 / 4, Sox2, Klf4 and c-Myc into mouse fibroblasts (Takahashi K., Yamanaka S., Cell, (2006) 126: 663-676), and human cell-derived iPS cells established by introducing the same four factors into human fibroblasts (Takahashi K., Yamanaka S. et al. Cell, (2007) 131: 861-872), Nanog-iPS cells established by introducing the above four factors and then screening using Nanog expression as an index (Okita, K., Ichisaka, T. and Yamanaka, S. (2007). Nature 448, 313-317), iPS cells generated by a method that does not include c-Myc (Nakagawa M., Yamanaka S. et al. Nature Biotechnology, (2008) 26, 101-106) and iPS cells established by introducing six factors by a virus-free method (Okita K. et al. Nat. Methods 2011 May; 8 (5): 409-12, Okita K. et al. Stem Cells. 31 (3): 458-66). Other available examples include induced pluripotent stem cells (Yu J., Thomson J.A. et al., Science (2007) 318: 1917-1920) produced by Thomson et al. and established by introducing four factors OCT3 / 4, SOX2, NANOG and LIN28, induced pluripotent stem cells (Park I.H., Daley GQ et al., Nature (2007) 451: 141-146), induced pluripotent stem cells (JP 2008-307007A) produced by Sakurada et al., etc.

[0090] Other examples are known in the art and are described in all published articles (e.g., Shi Y., Ding S. et al., Cell Stem Cell, (2008) Vol. 3, No. 5, 568-574; Kim JB, Scholer HR et al., Nature, (2008) 454, 646-650; Huangfu D., Melton, DA et al., Nature Biotechnology, (2008) 26, No. 7, 795-797) or any induced pluripotent stem cell disclosed in patents (e.g., JP2008-307007A, JP2008-283972A, US2008 / 2336610, US2009 / 047263, WO2007 / 069666, WO2008 / 118220, WO2008 / 124133, WO2008 / 151058, WO2009 / 006930, WO2009 / 006997 and WO2009 / 007852).

[0091] As induced pluripotent stem cell strains, various iPS cell strains established by NIH, RIKEN, Kyoto University, etc. can be used. Examples of human iPS cell strains include HiPS-RIKEN-1A strain, HiPS-RIKEN-2A strain, HiPS-RIKEN-12A strain, and Nips-B2 strain (RIKEN); Ff-I01s04 strain, QHJI strain, RWMH strain, DRXT strain, RJWI strain, YZWJ strain, ILCL strain, GLKV strain, 253G1 strain, 201B7 strain, 409B2 strain, 454E2 strain, 606A1 strain, 610B1 strain, and 648A1 strain (Kyoto University), etc.

[0092] "Nucleic acid" may be any molecule obtained by polymerizing nucleotides and molecules having the same function as nucleotides. Examples include RNA as a ribonucleotide polymer, DNA as a deoxyribonucleotide polymer, a polymer as a mixture of ribonucleotides and deoxyribonucleotides, and a nucleotide polymer containing nucleotide analogs. Nucleic acid may also be a nucleotide polymer containing a nucleic acid derivative. Nucleic acid may be a single-stranded nucleic acid or a double-stranded nucleic acid. Double-stranded nucleic acids include double-stranded nucleic acids in which one strand hybridizes with the other strand under stringent conditions.

[0093] Nucleotide analogs may be any molecules as long as they are obtained by modifying ribonucleotides, deoxyribonucleotides, RNA or DNA to improve nuclease resistance, stabilization, increase affinity with complementary strand nucleic acid, enhance cell permeability or visualization compared to RNA or DNA. Nucleotide analogs may be naturally occurring molecules or non-natural molecules. Examples include sugar-modified nucleotide analogs (e.g., 2'-O-methylribose substituted nucleotide analogs, 2'-O-propylribose substituted nucleotide analogs, 2'-methoxyethoxyribose substituted nucleotide analogs, 2'-O-methoxyethylribose substituted nucleotide analogs, 2'-O-[2-(guanidinium)ethyl]ribose substituted nucleotide analogs, 2'-fluororibose substituted nucleotide analogs, bridged nucleic acids (BNA), locked nucleic acids (LNA), ethylene bridged nucleic acids (ENA), peptide nucleic acids (PNA), oxygen peptide nucleic acids (OPNA) and peptide ribonucleic acids (PRNA)), phosphodiester bond-modified nucleotide analogs (e.g., phosphorothioate bond-substituted nucleotide analogs and N3'-P5' phosphoramidate bond-substituted nucleotide analogs), and the like.

[0094] Nucleic acid derivatives may be any molecules as long as it is a molecule obtained by adding another chemical substance to nucleic acid that improves nuclease resistance, stabilization, increased affinity with complementary nucleic acid, enhanced cell permeability or visualization compared to nucleic acid. Specific examples include 5'-polyamine-adduct derivatives, cholesterol-adduct derivatives, steroid-adduct derivatives, bile acid-adduct derivatives, vitamin-adduct derivatives, Cy5-adduct derivatives, Cy3-adduct derivatives, 6-FAM-adduct derivatives, biotin-adduct derivatives, etc.

[0095] The method for producing the T cell of the present invention (also simply referred to as "the production method of the present invention" in this specification) characteristically comprises the following steps.

[0096] Step (1) is a step of culturing a three-dimensional cell aggregate containing cells that can differentiate into T cells and stromal cells derived from pluripotent stem cells and expressing Notch ligands.

[0097] The production method including step (1) can efficiently induce differentiation into T cells. Referring to the description in WO2017 / 075389, etc., the culture of three-dimensional cell aggregates in step (1) can be carried out using cells that can differentiate into T cells and stromal cells expressing Notch ligands derived from pluripotent stem cells.

[0098] The cells capable of differentiating into T cells used in step (1) are not particularly limited as long as they are cells capable of differentiating into T cells. Examples include CD34 +cells, mesodermal progenitor cells, CD4CD8 double negative T cells, CD4CD8 double positive T cells, etc.; preferably CD34 + CD34 is more preferably a hematopoietic endothelial cell, a hematopoietic stem cell, a progenitor T cell or a mesodermal progenitor cell; and CD34 is particularly preferably a hematopoietic endothelial cell. + The cells are cells expressing CD34 (CD34 + ), and in particular cells expressing CD34 but not CD7 (CD34 + / CD7 - ). CD34 + Examples of cells include hematopoietic endothelial cells and hematopoietic stem cells.

[0099] The cells capable of differentiating into T cells used in step (1) are more preferably cells differentiated from pluripotent stem cells (particularly iPS cells (particularly human iPS cells)). Among them, the cells capable of differentiating into T cells used in step (1) are preferably cells differentiated from pluripotent stem cells (particularly iPS cells (particularly human iPS cells)) into CD34 + Cells (especially hemogenic endothelial cells).

[0100] Differentiation of pluripotent stem cells into CD34 + The cells can be induced according to known methods. When the pluripotent stem cells are iPS cells, the differentiation of hematopoietic progenitor cells can be induced, for example, by the methods disclosed in WO2017 / 221975, WO2018 / 135646 and Cell Reports 2 (2012) 1722-1735, thereby producing CD34 + When hemogenic endothelial cells are subjected to step (1), step (1) may be performed on a cell containing CD34 + The step (1) may be performed on hemogenic endothelial cells (i.e., the hemogenic endothelial cells are not isolated before performing step (1)), or step (1) may be performed on hemogenic endothelial cells isolated according to a known method (e.g., flow cytometry or magnetic cell separation method).

[0101] The stromal cells used are cells expressing Notch ligands and derived from pluripotent stem cells. Stroma cells are a general term for connective tissue cells that support parenchymal cells, and representative examples include fibroblasts, hemocytes, endothelial cells, smooth muscle cells, epithelial cells, and tissue stem cells. Stroma cells can be used alone or in combination of two or more. In addition, it is preferred that nucleic acids expressing Notch ligands are introduced into stromal cells. Stroma cells expressing Notch ligands can be produced by introducing the above-mentioned nucleic acids into stromal cells. Alternatively, it is also possible to produce stromal cells by introducing the above-mentioned nucleic acids into pluripotent stem cells (particularly iPS cells (especially human iPS cells)), and then differentiating pluripotent stem cells into stromal cells.

[0102] The matrix cell used in the production method of the present invention is a matrix cell differentiated from a pluripotent stem cell (particularly an iPS cell (particularly a human iPS cell)). In particular, it is desirable to use cells obtained by differentiating into fibroblasts by pluripotent stem cells (particularly an iPS cell (particularly a human iPS cell)). Pluripotent stem cells can be induced to differentiate into matrix cells according to known methods. When the pluripotent stem cell is a human iPS cell, for example, the differentiation of the iPS cell can be induced into fibroblasts by the method described in PLoS ONE 8 (10): e77673, 2013. Therefore, using the matrix cell derived from the pluripotent stem cell makes it possible to provide a method for producing T cells, which has higher safety in production compared to using primary cells or cell lines. Due to the use of the matrix cell derived from the pluripotent stem cell, there is almost no difference between the large number of feeder cells used, and T cells can be stably produced. In addition, as shown in the following examples, using the matrix cell derived from the pluripotent stem cell makes it possible to produce T cells with improved anticancer activity and cell dynamics.

[0103] Notch ligands are not particularly limited, and include canonical Notch ligands and non-canonical Notch ligands disclosed in WO2017 / 075389. Examples of canonical Notch ligands include DLL4 (delta-like ligand 4), DLL1 (delta-like ligand 1), JAG1 (Jagged 1), JAG2 (Jagged 2), etc. They can be used alone or in combination of two or more. Examples of non-canonical Notch ligands include contactin-1, NOV / CCN3, contactin-6, periostin / OSF-2, DLK2 / EGFL9, Pref-1 / DLK1 / FA1, DNER, thrombospondin-2, MAGP-1 / MFAP2, thrombospondin-3, MAGP-2 / MFAP5, thrombospondin-4, and spindle protein-1 (Netrin-1). It is preferred to use human DLL4 as a Notch ligand.

[0104] The method of introducing the nucleic acid expressing Notch ligand into stromal cells or pluripotent stem cells is not particularly limited, and various known or general methods can be used. Generally, the nucleic acid for expressing Notch ligand is introduced into stromal cells using an expression vector, and expressed. The expression vector can be linear or circular, and can be a non-viral vector (such as a plasmid), a viral vector or a transposon vector.

[0105] The method by which expression vector is introduced into stroma cells can be carried out according to the embodiment. For example, expression vector can be introduced into stroma cells by known methods such as virus infection method, calcium phosphate method, lipid transfection method, microinjection method or electroporation method. Expression vector can be prepared into the form suitable for use in each method by known means or suitably using commercially available test kit (according to its specification sheets).

[0106] The expression vector can be introduced into the matrix cells by a viral infection method. Examples of viral vectors include retroviral vectors, lentiviral vectors, adenoviral vectors and adeno-associated viral vectors. When these viral vectors are used, the corresponding commercially available kits can be used to transfect the vector containing the nucleic acid for expressing Notch ligands and the packaging vector (plasmid) of each virus into the host cell to produce recombinant viruses, and then the recombinant viruses obtained can be used to infect matrix cells.

[0107] In addition to the nucleic acid for expressing the Notch ligand, the expression vector may contain sequences such as a nuclear localization signal (NLS) and a multiple cloning site (MCS), if necessary. The expression vector may also contain nucleic acids (base sequences) encoding "functional genes", such as reporter genes (e.g., genes encoding fluorescent proteins of various colors), drug selection genes (e.g., kanamycin resistance gene, ampicillin resistance gene, and puromycin resistance gene), and suicide genes (e.g., genes encoding: diphtheria A toxin, herpes simplex virus thymidine kinase (HSV-TK), carboxypeptidase G2 (CPG2), carboxylesterase (CA), cytosine deaminase (CD), cytochrome P450 (cyt-450), deoxycytidine kinase (dCK), nitroreductase (NR), purine nucleoside phosphorylase (PNP), thymidine phosphorylase (TP), varicella zoster virus thymidine kinase (VZV-TK), xanthine-guanine phosphoribosyltransferase (XGPRT), inducible caspase 9, etc.).

[0108] The cells that can be differentiated into T cells and stromal cells can be derived from humans or mammals other than humans (non-human mammals), and preferably cells of human origin. From the perspective of no xenogeneicity, it is desirable to use cells of human origin. Examples of non-human mammals include mice, rats, hamsters, guinea pigs, rabbits, dogs, cats, pigs, cattle, horses, sheep and monkeys.

[0109] Three-dimensional cell aggregates can be formed, for example, by centrifuging cells that can be differentiated into T cells or cells differentiated therefrom and stromal cells expressing Notch ligands. The ratio of stromal cells to cells that can be differentiated into T cells is, for example, 100:1 to 1:100, 20:1 to 1:20 or 10:1 to 1:10, preferably 4:1 to 1:4, and more preferably 1:1.

[0110] The medium used for culturing the three-dimensional cell aggregate is not particularly limited, and examples include serum-free medium, and particularly serum-free medium containing insulin (and additionally biotin, transferrin, and albumin).

[0111] Examples of basal culture media for culturing three-dimensional cell aggregates include AIMV, X-VIVO-15, NeuroBasal, EGM2, TeSR, BME, BGJb, CMRL1066, Glasgow's MEM, modified MEM zinc selection, IMDM, 199 culture medium, Eagle's MEM, αMEM, DMEM, Ham, RPMI-1640, Fisher's medium, etc. These culture media can be used alone or as a mixture of two or more. In addition, for example, the culture medium components disclosed in WO2017 / 075389 can be appropriately added.

[0112] As the culture conditions for culturing the three-dimensional cell aggregates, for example, the culture temperature is about 20 to 40° C., the CO2 concentration is about 2 to 10%, the oxygen concentration is about 1 to 20%, and the culture period is, for example, about 1 to 12 weeks, preferably 3 to 10 weeks, and more preferably 6 to 9 weeks. The cell density at the start of the culture may be, for example, about 1.0×10 4 to 1.0×10 10 cells / mL.

[0113] The culture medium, culture conditions and the like used in the production method of the present invention may be those suitable for the type of cells to be cultured.

[0114] The basal medium used as such a medium is not particularly limited as long as it can be used to culture animal cells. Examples include those mentioned above.

[0115] The culture medium may contain serum or may not contain serum. The culture medium may also contain serum substitutes (e.g., albumin, transferrin, Knockout serum substitute (KSR), fatty acids, insulin, collagen precursors, trace elements, 2-mercaptoethanol, 3'-thioglycerol, and ITS-supplements). Serum substitutes may be used alone or in combination of two or more.

[0116] The culture medium may further contain one or more of the following substances: lipids, amino acids (non-essential amino acids, etc.), L-glutamine, vitamins, growth factors, cytokines, antibiotics, antioxidants, pyruvic acid, buffers, inorganic salts, etc. As the culture medium, it is desirable to use a chemically defined culture medium that does not contain substances with unknown components (such as serum) because the culture medium variation between batches can be reduced and cells of stable quality can be prepared.

[0117] The pH of the culture medium is generally 7.0 to 7.8, and preferably 7.2 to 7.6. In order to prevent contamination before use, the culture medium is preferably sterilized by a method such as filtration, UV irradiation, heat sterilization or radiation. Cultivation is carried out in the presence or absence of feeder cells. The culture conditions are not particularly limited, and conditions commonly used for cell culture can be used. In cultivation, multiple passages can be performed as needed to obtain the cells of the desired amount, or the addition and replacement of the culture medium can be performed. The culture vessel is not particularly limited, and can be appropriately selected from plates, dishes, culture dishes, flasks, bags, bottles, grooves (culture tanks), bioreactors, etc.

[0118] The production method of the present invention may further include separating the obtained T cells to concentrate the T cells. T cells can be separated by a known method, such as a method using flow cytometry or a magnetic cell separation method.

[0119] The T cells obtained by the production method of the present invention are CD3 + cells, and examples include helper T cells, which are CD4 + T cells, cytotoxic T cells, which are CD8 + T cells, regulatory T cells, Tfh cells (CXCR5 + cells), γδT cells, NKT cells (CD56 + cells), naive T cells (CD45RA + CCR7 + cells), central memory T cells (CD45RA - CCR7 + cells), effector memory T cells (CD45RA - CCR7 - cells), terminal effector T cells (CD45RA + CCR7 - Cells) etc. Among them, CD4 + T cells, CD8 + T cells, γδ T cells, and regulatory T cells. T cells can be only one type, or a mixture of two or more types.

[0120] In one aspect of the present invention, the production method of the present invention allows the preparation of a cell population derived from pluripotent stem cells (preferably iPS cells (more preferably human iPS cells)), wherein the αβT cells contained in the cell population have CD4 + T cells and CD8 + The production method of the present invention is characterized in that even if the step of separating T cells from cells that can differentiate into T cells is not included in the process of producing T cells, CD4 + T cells and CD8+ When the method does not include the step of isolating T cells, the cell population can be produced more efficiently than when the method includes the step. + T cells and CD8 + Among the αβT cells contained in the T cell population, CD4 + T cells and CD8 + The ratio (number of cells) of T cells is, for example, 0.1 or more, 0.2 or more, 0.3 or more, 0.4 or more, 0.5 or more, 0.6 or more, 0.7 or more, 0.8 or more, 0.9 or more, 1.0 or more, 1.1 or more, 1.2 or more, 1.3 or more, 1.4 or more, 1.5 or more, 1.6 or more, 1.7 or more, 1.8 or more, 1.9 or more, The ratio is preferably 0.6 or more, more preferably 1.0 or more, and even more preferably 2.0 or more. The upper limit of the ratio is, for example, 10, 9.0, 8.0, 7.0, 6.0 or 5.0.

[0121] The T cells obtained by the production method of the present invention may be T cells into which foreign genes have been introduced.

[0122] The "foreign gene" is a gene introduced from the outside in order to express a desired protein in T cells, and can be appropriately selected according to the purpose of the T cells.

[0123] One or more genes can be introduced into the T cells obtained by the production method of the present invention as exogenous genes, and the exogenous gene can be, for example, a nucleic acid encoding an exogenous T cell receptor (TCR) or a chimeric antigen receptor (CAR). Exogenous genes can be, for example, genes for expressing CAR, and can further contain genes for expressing cytokines and / or chemokines (for example, wherein IL-15 and IL-15Rα fusion proteins (IL-15Rα / IL-15) are connected). As with general or known CAR, the CAR expressed by T cells is substantially configured to make (i) recognize the antigen recognition site (for example, single-chain antibody) of the cell surface antigen of cancer cells, (ii) transmembrane region, and (iii) peptides at the site of the signal transduction region inducing T cell activation are connected via a spacer as required. TCR can be a dimer of α chain and β chain or γ chain and δ chain. Exogenous TCR means that it is exogenous for the T cells into which the nucleic acid encoding exogenous TCR is to be introduced. The amino acid sequence of exogenous TCR may be the same or different from the amino acid sequence of the endogenous TCR of T cells. When the exogenous gene to be introduced is a nucleic acid encoding an exogenous T cell receptor, an example of the nucleic acid is a nucleic acid encoding Vg9Vd2TCR.

[0124] Examples of methods for introducing foreign genes into cells include the above methods. The cells into which foreign genes are introduced are not particularly limited and may be at any stage of differentiation. Examples include pluripotent stem cells (particularly iPS cells), cells that can differentiate into T cells, T cells, etc.

[0125] Other examples of one or more exogenous genes introduced into T cells obtained by the production method of the present invention include expression constructs, which include (a) CNS1 (conserved non-coding sequence 1), CNS2 (conserved non-coding sequence 2) and CNS3 (conserved non-coding sequence 3) of the Foxp3 gene, (b) a promoter, and (c) a nucleic acid encoding FOXP3 (which may be referred to as "expression construct" or "CNS-Foxp3" in this specification). By introducing such an expression construct into pluripotent stem cells, cells that can be differentiated into regulatory T cells, etc., regulatory T cells can be efficiently produced. The expression construct is not particularly limited as long as it can express FOXP3. In addition to (a), (b) and (c) mentioned above, the expression construct preferably contains a terminator, a polyadenylation signal, Foxp3 3'UTR, etc., and is more preferably an expression construct introduced into these cells that functions in the cells.

[0126] The base sequence of the human Foxp3 gene is registered as RefSeq accession number NM_001114377 (SEQ ID No. 1) and NM_014009 (SEQ ID No. 2), and its amino acid sequence is also registered as RefSeq accession number NP_001107849 (SEQ ID No. 3) and NP_054728 (SEQ ID No. 4). These RefSeq IDs are registered on the NCBI website. In the present invention, the above-mentioned genes also include degenerate products and variants of genes other than the genes having the base sequences registered in the above-mentioned databases. Desired variants are those that encode proteins having biological activities equivalent to those of the proteins consisting of the above-mentioned amino acid sequences. Examples of variants include FOXP3 variants having an amino acid sequence that is 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more identical to the native amino acid sequence. In this specification, FOXP3 refers to a protein, and Foxp3 refers to a gene; however, when this interpretation is appropriate, FOXP3 and Foxp3 refer to a gene and a protein, respectively.

[0127] The nucleic acid encoding FOXP3 is not particularly limited as long as it is a nucleic acid encoding FOXP3 protein, and is preferably cDNA of FOXP3.

[0128] CNS1, CNS2 and CNS3 used in the present invention are all derived from Foxp3 gene. CNS1, CNS2 and CNS3 are Foxp3 enhancer elements. The promoter used in the present invention is not particularly limited, and examples include CAG promoter, ubiquitin gene promoter, Foxp3 gene promoter, EF1α promoter, SRα promoter, SV40 promoter, LTR promoter, cytomegalovirus (CMV) promoter, Rous sarcoma virus (RSV) promoter, Moloney murine leukemia virus (MoMuLV) LTR, herpes simplex virus thymidine kinase (HSV-TK) promoter, etc.; and preferably Foxp3 gene promoter. Preferred examples of the base sequences of CNS1, CNS2, CNS3 and promoter of human Foxp3 gene include base sequences represented by SEQ ID No.5 to 8, respectively. Even if promoter, CNS1, CNS2 and CNS3 do not have the above base sequences, promoter, CNS1, CNS2 and CNS3 also include variants. Desired variants are those variants having biological activities equivalent to the promoter, CNS1, CNS2 and CNS3 consisting of the above-mentioned base sequences. Examples of variants include those variants having base sequences, and the base sequences have 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more identity with the natural base sequence.

[0129] The arrangement (order) of the promoter, CNS1, CNS2, CNS3 and the nucleic acid encoding FOXP3 in the expression construct is not particularly limited. Preferably, CNS1, CNS2 and CNS3 are located upstream of the promoter; and more preferably, the order of CNS1, CNS2, CNS3, the promoter and the nucleic acid encoding FOXP3 is from the 5' end side.

[0130] It is desirable to use pluripotent stem cells (particularly iPS cells) as cells into which expression constructs are introduced, inducing these cells to differentiate into CD34 + cells (especially hemogenic endothelial cells), and then CD34 + Cells, in particular hemogenic endothelial cells, are subjected to the production method of the invention to differentiate them into regulatory T cells.

[0131] The T cells produced by the production method of the present invention can be used to prevent and / or treat T cell-related diseases. + T cells, CD8 +When T cells or γδT cells, these cells can be used for example but not limited to the treatment and prevention of tumors (hematological tumors and solid tumors), infection, blood diseases, etc. When the T cells produced by the production method of the present invention are regulatory T cells, the cells can be used for the treatment and prevention of animals (particularly people) with abnormally enhanced immune responses. For example, regulatory T cells can be used for the treatment and prevention of immune disorders, polyendocrine gland diseases, enteropathy, X-linked (IPEX) syndrome, graft-versus-host disease (GVHD), organ transplant rejection, autoimmune diseases, inflammatory diseases, allergic diseases (hay fever, asthma, atopic dermatitis, eczema, food allergic reactions, food hypersensitivity reactions, urticaria, allergic rhinitis, allergic conjunctivitis and drug allergies), etc. The T cells produced by the production method of the present invention can be used for autologous transplantation or allogeneic transplantation. In addition, T cells can be used in combination with other drugs.

[0132] When such cell therapy is performed, from the viewpoint of preventing rejection, the subject from which cells are separated for producing T cells preferably has the same HLA type as the subject to which the T cells are administered, and more preferably the same HLA type as the subject to which the T cells are administered.

[0133] The present invention can produce a drug comprising T cells (hereinafter also referred to as "the drug of the present invention"). The drug of the present invention is preferably produced as a parenteral preparation by mixing an effective amount of T cells with a pharmaceutically acceptable carrier according to a known method (e.g., a method described in the Japanese Pharmacopoeia). The drug of the present invention is preferably prepared as a parenteral preparation, such as an injection, a suspension or an infusion. Examples of parenteral administration methods include intravenous, intraarterial, intramuscular, intraperitoneal or subcutaneous administration. Examples of pharmaceutically acceptable carriers include solvents, substrates, diluents, excipients, soothing agents, buffers, preservatives, stabilizers, suspending agents, isotonic agents, surfactants, solubilizing agents, etc.

[0134] The dosage of the drug of the present invention can be appropriately determined according to various conditions, such as the patient's weight, age, sex and symptoms. Generally, the drug of the present invention is administered so that the number of cells per administration for a subject weighing 60 kg is generally 1×10 6 Up to 1×10 10 cells, preferably 1×10 7 Up to 1×10 9 cells, and more preferably 5×10 7 Up to 5×10 8Cells. The medicine of the present invention can be administered once or several times. The medicine of the present invention may have a known form suitable for parenteral administration, such as injection or infusion. In addition, the medicine of the present invention may contain physiological saline, phosphate buffered saline (PBS), culture medium, etc. to stably maintain cells. The culture medium may be, for example, but not limited to RPMI, AIM-V, X-VIVO10 or other culture medium. In addition, for the purpose of stability, a pharmaceutically acceptable carrier (e.g., human serum albumin), a preservative, etc. may be added to the medicine. The medicine of the present invention is applied to mammals, including humans.

[0135] As used in this specification and claims, unless the context requires otherwise, singular terms shall include pluralities and plural terms shall include the singular. Therefore, unless otherwise expressly indicated, singular articles (e.g., in the case of English, "a / an", "the", etc.) should also be understood to include the concept of their plural forms.

[0136] Example

[0137] Examples are provided below to explain the present invention in more detail. However, the present invention is not limited to these examples.

[0138] 1) Preparation of iPS cell-derived fibroblasts / DLL4 cells

[0139] To be used as feeder cells when inducing T cell differentiation from iPS cells, fibroblasts were differentiated from iPS cells (Ff-I01s04 strain: derived from healthy peripheral blood mononuclear cells) provided by the Center for iPS Cell Research and Application, Kyoto University. Subsequently, cells forcibly expressing DLL4, a Notch ligand, were generated using lentivirus under the control of the EF1α promoter.

[0140] Specifically, the Ff-I01s04 strain was cultured at 1×10 610 cells / well were seeded in a 6-well plate (Corning) that had been subjected to ultra-low adhesion treatment in a medium supplemented with AK03N (Ajinomoto Co., Inc.), Y-27632 (FUJIFILM Wako Pure Chemical Corporation), and CHIR990211 (Tocris) (day 0). The next day, cells were seeded in 10 cm culture dishes (Corning) coated with 0.1% gelatin (Nacalai Tesque, Inc.) in fibroblast medium (supplemented with 20% FBS (Corning), 10 μg / ml human insulin, 5.5 μg / ml human transferrin, 5 ng / ml sodium selenite (ITS, Gibco), 2 mM L-glutamine, 100 U / ml penicillin, 100 μg / ml streptomycin (PSG, Sigma-Aldrich) and 50 μg / ml ascorbic acid 2-phosphate (Sigma-Aldrich) α-MEM (Invitrogen)) (Day 1). The medium was changed twice a week, and culture was continued for 7 days to obtain a cell population containing fibroblasts (Day 8).

[0141] The iPS cell-derived fibroblasts were cultured at 1×10 5 The cells / well were seeded in a 24-well plate coated with gelatin, and the next day, a lentiviral solution carrying the human DLL4 gene introduced downstream of the EF1α promoter and protamine at a final concentration of 10 μg / mL were added to prepare iPS cell-derived fibroblast / DLL4 cells (iFibro / DLL4).

[0142] The prepared cells were stained with anti-DLL4 antibody-APC (BioLegend) or anti-CD90 antibody-APC (BioLegend), which is a fibroblast marker, and analyzed by flow cytometry. As a result, the expression of DLL4 and fibroblast markers, such as Figure 1 as shown in .

[0143] 2) Preparation of iPS cells (QHJI01s04 / G9D2 cells) with Vg9Vd2TCR

[0144] According to the method described in WO2020 / 013315, the Vg9Vd2TCR gene was introduced into iPS cells (QHJI01s04 strain: derived from healthy peripheral blood mononuclear cells) provided by the iPS Cell Research and Application Center of Kyoto University to prepare iPS cells introduced with Vg9Vd2TCR.

[0145] Specifically, iPS cells were cultured at 1×10 4Cells / well were seeded in a 24-well plate, and on the next day, a lentiviral solution carrying the Vg9Vd2 TCR gene incorporated downstream of a human ubiquitin promoter and protamine at a final concentration of 10 μg / mL were added to prepare QHJI01s04 / G9D2 cells.

[0146] 3) Induction of iPS cell differentiation into HEC

[0147] The cell population containing hemogenic endothelial cells used is a floating cell population differentiated from iPS cells (Ff-I01s04 strain: derived from healthy peripheral blood mononuclear cells) provided by the iPS Cell Research and Application Center of Kyoto University by known methods (e.g., the methods disclosed in Cell Reports 2 (2012) 1722-1735 and WO2017 / 221975).

[0148] Specifically, the Ff-I01s04 strain was cultured at 1×10 6 Cells / well were seeded in 6-well plates (Corning) that had been subjected to ultra-low adhesion treatment (Day 0). 50ng / ml BMP4 (R&D systems), 50ng / ml bFGF (FUJIFILM WakoPure Chemical Corporation), 50ng / ml VEGF (R&D systems) and 2μM SB431542 (FUJIFILM Wako Pure Chemical Corporation) were added to EB culture medium (StemPro34 (Gibco) supplemented with 10μg / ml human insulin, 5.5μg / ml human transferrin, 5ng / ml sodium selenite (ITS, Gibco), 2mM L-glutamine (Sigma-Aldrich), 45mMα-monothioglycerol (Nacalai Tesque, Inc.) and 50μg / ml ascorbic acid 2-phosphate (Sigma-Aldrich)), and the cells were cultured under hypoxic conditions (5% O2) for 4 days (Day 4). Subsequently, the cells were further cultured for 4 days (Day 8) in a medium supplemented with 50 ng / ml bFGF, 50 ng / ml VEGF, and 50 ng / ml SCF (R&D systems) to obtain a cell population containing HECs. The floating cell population containing HECs was stained using the antibody panel in Table 1 below.

[0149] Table 1

[0150] Antibody supplier Fluorescent labeling Anti-CD34 antibody Abcam PE / Cy7 Anti-CD43 antibody BD BV510 Anti-CD73 Antibody BD APC Anti-CD184 antibody BD BV421 Anti-CD235a antibody BioLegend FITC Anti-CD14 antibody BioLegend APC / ef780

[0151] The obtained cell population contained about 15% HEC (CD34 + / CD43 - / CD73 - / CD184 - In addition, a cell population containing HEC was obtained from QHJI01s04 / G9D2 cells in the same manner as above, except that the QHJI01s04 / G9D2 cells produced in 2) above were used instead of the Ff-I01s04 strain.

[0152] 4) Induction of T cell differentiation

[0153] Referring to the description in WO2017 / 075389 and the like, the iFibro / DLL4 obtained in 1) above and the HEC-containing cell population obtained in 3) above are allowed to differentiate into T cells.

[0154] Specifically, iFibro / DLL4 or mouse stromal cell line MS5 (MS5 / DLL4) that forcedly expresses DLL4 was used as a support, and each was co-cultured with iPS cell-derived HEC produced in 3) above at a cell ratio of 1:1 or 4:1. The culture medium used was RPMI-1640 (FUJIFILM Wako Pure Chemical Corporation) containing a final concentration of 2x B27 supplement (Invitrogen), 1x PSG (Sigma-Aldrich), 1xGlutamax (Invitrogen), 5ng / mL IL-7 (PeproTech), 5ng / mL FlT3L (PeproTech) and 50μg / mL ascorbic acid (Sigma-Aldrich). The cells co-cultured on 30mm Millicell (hydrophilic PTFE, pore size: 0.4μm, height: 5mm, MerckMillipore) were placed in a 6-well plate (TPP) and cultured for 9 weeks, while the culture medium was replaced every three or four days.

[0155] After culture, the obtained cells were collected and amplified according to the method described in WO2020 / 032179, and then the anti-CD19-CAR (SEQ ID No: 9) gene and IL-15Rα / IL-15 (SEQ ID No: 10) gene were introduced. As a result, iPS cell-derived CD19CAR T cells were obtained. Intracellular staining was performed using the antibody panel in Table 2 below, and the expression of T cell surface molecules and anti-CD19 CAR and IL-15Rα was confirmed by flow cytometry, as shown in Table 2. Figure 2 as shown in .

[0156] Table 2

[0157] Antibody supplier Fluorescent dyes Anti-CD3Σ Antibody BioLegend APC / Cy7 Anti-CD4 antibody BioLegend BV421 Anti-CD8α antibody BioLegend PerCP / Cy5.5 Anti-CD8β Antibody eBioscience PE / Cy7 Anti-TCRαβ Antibodies eBioscience PE Anti-IL15Rα Antibody BioLegend APC Anti-CD19CAR Antibody Acrobio FITC

[0158] 5) In vivo efficacy and cell kinetics (CK)

[0159] The drug efficacy and cell kinetics of the iPS cell-derived CD19CAR T cells prepared in 4) above were examined in an immunodeficient mouse cancer model.

[0160] Specifically, 8-week-old NOD.Cg-Prkdc scid Iq tm1Wjl / SzJ (NSG) mice (Charles River Japan, Inc.) were intravenously administered with 5×10 5 Nalm6 (a cell line derived from human B-cell leukemia cells) transfected with luciferase was added to 10 cells / 200 μL, and 4 days later, the CD19CAR T cells prepared in 4) above were intravenously administered in the composition shown in Table 3.

[0161] Table 3

[0162]

[0163] Starting one week after administration of CD19CAR T cells, 3 mg of VivoGlo fluorescein (Promega) was administered intraperitoneally to each mouse, and 10 minutes later, the remaining cancer cells were visualized using IVIS Lumina II (Perkin Elmer). At the same time, body weight was measured and blood was collected using heparinized tubes. The collected blood was stained with the antibody panel in Table 4, then hemolyzed and fixed with FACS lysate (BD), and analyzed using FACS LSR Fortessa (BD). CD45 + The cells were regarded as CD19CAR T cells for calculation of CK.

[0164] Table 4

[0165] Antibody supplier Fluorescent dyes Anti-CD45 antibody BioLegend BV510 Anti-CD4 antibody BioLegend BV421 Anti-CD19 antibodies BioLegend APC / Cy7 Anti-CD8β Antibody eBioscience PE / Cy7 Anti-CD3 Antibodies BioLegend APC Anti-TCRαβ Antibodies eBioscience PE

[0166] Results, such as Figure 3 As shown in , the number of cancer cells in all CD19CAR T cell administration groups was significantly reduced compared with the control group, thereby demonstrating strong drug efficacy. In addition, in the comparison between CD19CAR T cells, cells prepared using iFibro / DLL4 as a support showed stronger drug efficacy than cells prepared using MS5 / DLL4 as a support. In addition, as Figure 4 As shown in , the number of CD19CAR T cells retained in mice tends to be positively correlated with drug efficacy.

[0167] 6) CD4 + T cells and CD8 + The proportion of T cells in the differentiated T cell population

[0168] In the iPS cell-derived T cell population prepared in 4) above (cell population before introduction of anti-CD19-CAR gene and IL-15Rα / IL-15 gene), CD4 + T cells and CD8 + The proportion of T cells in αβT cells (%), and CD4 + T cells and CD8 + As a result, as shown in Table 5, it was found that the T cell population prepared using iFibro / DLL4 as a support had a higher CD4 + T cell ratio (CD4 + T cells and CD8 + The proportion of T cells shows the mean value).

[0169] Table 5

[0170]

[0171] 7) Differentiation of iPS cells into Treg and detection of protein expression levels

[0172] The differentiation of iPS cells into Tregs is as follows. A plasmid sequence was designed and synthesized, in which a DNA sequence in which the mStrawberry protein sequence (MK012431) registered in GenBank was changed to a dTomato sequence was incorporated into a transfer plasmid for the production of a third-generation lentiviral vector. This plasmid was transfected into HEK293 cells together with a packaging plasmid and an envelope plasmid for the production of a lentiviral vector, and the supernatant containing the produced lentiviral vector was collected and then concentrated by high-speed centrifugation to obtain the lentiviral vector to be introduced into iPS cells. Next, the Ff-I01s04 strain was cultured at 1×10 4 Cells / well were seeded in a 24-well plate, protamine was added to a final concentration of 10 μg / mL, and then a lentiviral solution carrying the incorporated CNS-Foxp3 was directly added to generate virus-infected iPS cells.

[0173] The virus-infected Ff-I01s04 strain was cultured at 1×10 6Cells / well were seeded in 6-well plates (Corning) that had been subjected to ultra-low adhesion treatment (day 0). 50ng / ml BMP4 (R&D systems), 50ng / ml bFGF (FUJIFILM Wako Pure Chemical Corporation), 50ng / ml VEGF (R&D systems) and 2μM SB431542 (FUJIFILM Wako Pure Chemical Corporation) were added to EB culture medium (supplemented with 10μg / ml human insulin, 5.5μg / ml human transferrin, 5ng / ml sodium selenite (ITS, Gibco), 2mM L-glutamine (Sigma-Aldrich), 45mMα-monothioglycerol (Nacalai Tesque, Inc.) and 50μg / ml ascorbic acid 2-phosphate (Sigma-Aldrich) StemPro34 (Gibco)), and cells were cultured under hypoxic conditions (5% O2) for 4 days. Subsequently, the cells were further cultured for 4 days in a culture medium supplemented with 50ng / ml bFGF, 50ng / ml VEGF and 50ng / ml SCF (R&D systems) to obtain a cell population containing HEC. In addition, iFibro / DLL4 obtained in 1) above was used as a support and co-cultured with HEC derived from human iPS cells introduced into CNS-Foxp3 at a cell ratio of 1:1. The culture medium used was RPMI-1640 (FUJIFILM Wako Pure Chemical Corporation) containing a final concentration of 2xB27 supplements (Invitrogen), 1x PSG (Sigma-Aldrich), 1x Glutamax (Invitrogen), 5ng / mL IL-7 (PeproTech), 5ng / mL FlT3L (PeproTech) and 50μg / mL ascorbic acid (Sigma-Aldrich). The cells co-cultured on 30 mm Millicell (hydrophilic PTFE, pore size: 0.4 μm, height: 5 mm, Merck Millipore) were allowed to stand in a 6-well plate (TPP) and cultured for 9 weeks while replacing the medium every three or four days.

[0174] The cell population containing CNS-Foxp3-introduced human iPS cell-derived Tregs was cultured at 2.5 × 10 5Cells / well were seeded in a 48-well cell culture plate combined with an anti-CD3 antibody (eBioscience), cultured in a CO2 incubator at 37°C and 5.0% CO2 for 3 days, and then seeded in a 24-well G-Rex cell culture plate and continued to be cultured. The culture medium used was α-MEM (Invitrogen) containing final concentrations of FBS (15%, Corning), L-glutamine-penicillin-streptomycin solution (1 / 100, Invitrogen, Sigma-Aldrich), insulin-transferrin-selenium supplement (1 / 100, Invitrogen), ascorbic acid 2-phosphate (50 μg / mL, Sigma-Aldrich), IL-2 (10 ng / mL, PeproTech), anti-CD30 antibody (1.5 μg / mL, R&D systems), rapamycin (10 nM, LKT Laboratories) and anti-TNFR2 antibody (3 μg / mL, HycultBiotech). In the first three days, anti-CD28 antibody (1.5 μ g / mL, BioLegend) was further added to the above formulation. The cells thus obtained were separated according to the recommended protocol of CD4 MicroBeads (Miltenyi Biotec) to obtain CD4 positive cells. The cells were expanded once in the same manner (day 0), and then further cultured for 18 days (day 18) in the same culture medium supplemented with IL-3 (60 ng / mL, BioLegend), IL-4 (30 ng / mL, BioLegend), IL-33 (30 ng / mL, BioLegend) and TGF-β1 (5 ng / mL, BioLegend). Each cell population was stained with the following antibody panels (Group 1: Zombie NIR, BV510 CD3, BV421 CD4, PE / Cy7 CD8b, APC CD25, PE GZMB, AF488 FOXP3, PerCP / Cy5.5 CTLA4; Group 2: Zombie NIR, BV510 CD3, BV421 CD4, PE / Cy7 CD8b, AF488 FOXP3, PE Helios).

[0175] Results, such as Figure 5 As shown in , 31.0% of cells differentiated into Tregs in the first expansion culture (day 0), and the Treg population was further enriched to 77.1% (day 18) by the second expansion culture.

[0176] This application is based on Japanese Patent Application No. 2022-016271 filed in Japan on February 4, 2022, the entire contents of which are incorporated herein.

Claims

1. A method for producing T cells, the method comprising: Step (1) culturing three-dimensional cell aggregates, wherein the three-dimensional cell aggregates contain cells capable of differentiating into T cells and matrix cells derived from pluripotent stem cells and expressing Notch ligands.

2. The method according to claim 1, wherein the cells capable of differentiating into T cells are CD34 + cells or mesodermal progenitor cells.

3. The method according to claim 1, wherein the cell capable of differentiating into a T cell is a hematopoietic stem cell, a hematopoietic endothelial cell, a progenitor T cell or a mesodermal progenitor cell. The method according to claim 1 , wherein the cells capable of differentiating into T cells are hemogenic endothelial cells. The method according to claim 1 , wherein the cells capable of differentiating into T cells are cells derived from pluripotent stem cells. The method according to claim 1 , wherein the cells capable of differentiating into T cells are cells derived from iPS cells.

7. The method according to claim 1, wherein the stromal cells are fibroblasts.

8. The method according to claim 1, wherein the pluripotent cells are iPS cells.

9. The method according to claim 1, wherein the Notch ligand is at least one member selected from the group consisting of DLL4, DLL1, JAG1 and JAG2.

10. The method according to claim 1, further comprising before step (1): Step (2) inducing pluripotent stem cells to differentiate into stromal cells.

11. The method according to claim 6, further comprising before step (1): Step (3) induces iPS cells to differentiate into cells capable of differentiating into T cells.

12. The method according to claim 1, further comprising before step (1): Step (4) introduces nucleic acid encoding exogenous T cell receptor and / or chimeric antigen receptor into cells capable of differentiating into T cells.

13. The method according to claim 11, further comprising before step (3): Step (5) introduces nucleic acid encoding exogenous T cell receptor and / or chimeric antigen receptor into iPS cells.

14. The method according to claim 1, which is a method for producing T cells, wherein the T cells contain a protein selected from the group consisting of CD4 + T cells, CD8 + At least one of the group consisting of T cells, γδ T cells and regulatory T cells.

15. T cells obtained by the method of claim 1.

16. A medicine comprising the T cell according to claim 15.

17. A method for producing T cells expressing exogenous T cell receptors and / or chimeric antigen receptors, comprising: Step (6) introduces nucleic acid encoding exogenous T cell receptor and / or chimeric antigen receptor into T cells obtained by the method of claim 1. The drug according to claim 16, which is a preventive and / or therapeutic agent for T cell-related diseases. The medicament according to claim 18 , wherein the T cell-related disease is a tumor, an infection or a blood disease.

20. A method for preventing and / or treating a T cell-related disease, comprising administering the T cell according to claim 15 to a subject in need thereof.

21. The method of claim 20, wherein the T cell-related disease is a tumor, an infection or a blood disease.

22. The T cell according to claim 15, which is used for preventing and / or treating a T cell-related disease.

23. The T cell according to claim 22, wherein the T cell-related disease is a tumor, an infection or a blood disease.

24. Use of the T cell according to claim 15 in the production of a medicament for preventing and / or treating a T cell-related disease.

25. The use according to claim 24, wherein the T cell-related disease is a tumor, an infection or a blood disease.